Register before Dec. 27th and save up to $400!

Dear Colleague,

To address the continuing advances in disease therapies, as well as solving unmet needs of ocular disease drug therapies in aging individuals, GTC is proud to announce its 4th Ocular Diseases & Drug Discovery Conference, taking place on February 27-28, 2012 in Las Vegas, Nevada. Several companies have taken the initiative in developing ocular disease therapies, with exciting new developments in kinase inhibitors. These companies include Pfizer, EyeGate, Aciont, Genzyme, 3T Ophthalmics, Neurotech, Xcovery, Mystic Pharma, Aptar Pharma and many more.

To help promote the discovery of ocular disease and drug development, GTC is bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research and drugs available in combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, uveitis and other eye diseases at the 4th Ocular Diseases & Drug Discovery Conference.

The 4th Ocular Diseases & Drug Discovery Conference is one of four tracks in the Targets and Strategies in Drug Discovery Summit to be held at the Red Rock Resort and Spa in Las Vegas, NV on Feb. 27-28, 2012.  The other conferences that make up the summit are:

- 3rd Cancer Targets and Therapeutics
- Oncology Partnering & Deal-Making Conference
- 2nd Ubiquitin Research and Drug Discovery


Register for the All Summit Pass.  The pass gives you access to all four tracks!
Or bring your whole team! Register 3 for the price of 2 by using COUPON CODE: RCDVB.
 

UPCOMING CONFERENCES

Glenwood G. Gum, M.S., PhD, Associate Director, Preclinical Laboratory Operations, Absorption Systems

Patrick Healy, MPH, Chief Executive Officer, Trial Runners

Jing-Feng Huang, Director, Translational Medicine, Pfizer

Jeff Jamison, Ph.D., Chief Executive Officer, Ophthy-DS

Konrad Kauper, Ph.D., Director, Neurotech

M. Ken Kengatharan, Ph.D., President and Chief Scientific Officer, Altheos

Casey Kopczynski, Chief Scientific Officer, Aerie Pharmaceuticals

Achim Krauss, Ph.D., Director, GlaxoSmithKline

Kenneth J. Mandell, M.D., Ph.D., President and Chief Operating Officer, Xcovery Vision, Research Affiliate, Massachusetts Institute of Technology (MIT)

Kongnara Papangkorn, Ph.D., Research Director, Aciont

Mike Patane, Ph.D., Chief Scientific Officer, R&D, EyeGate Pharmaceuticals

Abraham Scaria, Ph.D., Senior Scientific Director, Genzyme

Timothy Sullivan, President and Chief Executive Officer, Mystic Pharmaceuticals

Carol Toris, Ph.D., Professor and Director, Ophthalmology, University of Nebraska Medical Center

Jenny W. Wang, Ph.D., Principal Scientist, Allergan

Barbara Wirostko, M.D., Clinical Adjunct Associate Professor, Ophthalmology, University of Utah; Altheos

David Woodward, Ph.D, Investigator, Senior RSRCH BI, Allergan

Sign up before Dec. 27th and receive an instant 20% discount off our regular rates!